Mechanism of cell death induced by cis-3,4′,5-trimethoxy-3′-aminostilbene in ovarian cancer

被引:11
作者
Durrant, David [1 ,2 ]
Richards, Joanna E. [1 ,2 ]
Walker, Winston T. [1 ,2 ]
Baker, Kristen A. [1 ,2 ]
Simoni, Daniele [3 ]
Lee, Ray M. [1 ,2 ]
机构
[1] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23298 USA
[3] Univ Ferrara, Dipartimento Sci Farmaceut, I-44100 Ferrara, Italy
关键词
stilbenes; ovarian cancer; therapy; signal transduction; cell cycle; mitochondria;
D O I
10.1016/j.ygyno.2008.02.031
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Stilbene derivative, cis-3,4',5-trimethoxy-3'-aminostilbene(stilbene 5c), is highly potent to induce cell death in ovarian cancer cells. This study is to investigate its mechanism to induce cell death. Methods. UCI101 ovarian cancer cells were used for this study. Cell death was analyzed by Alamar blue staining. Cell cycle was analyzed by flow cytometry after PI staining. Mitochondrial potential and reactive oxygen species were determined by MitoTracker green and DCF-DA, respectively. Immuno fluorescent staining was done with tubulin antibody following by confocal microscope examination. Cell lysates were collected after treatment with stilbene 5c for Western blotting analysis of various cell cycle regulators and signal transduction mediators. Results. Stilbene-treated cells die in both cell cycle-dependent and -independent pathways. Low concentration (30 nM) induces cell death without cell cycle arrest. This process involves disruption of mitochondrial potential and production of ROS by a Bcl-2-independent pathway. Higher concentration of stilbene 5c arrests cell cycle in G(2)/M phase, which is supported by dephosphorylation of Cdc2 and Cdc25C, and transiently elevation of spindle checkpoint BubR1. Although phosphorylation of Chk1 and Chk2 both increases after treatment, loss of Chk1 suppresses, whereas loss of Chk2 enhances, stilbene 5c-induced cell death. Phosphorylation of Akt and Stat3, but not MAPK, is suppressed after stilbene 5c treatment. Conclusion. These studies provide a mechanistic insight in using stilbenes in ovarian cancer. Stilbenes could be potentially useful agents for ovarian cancer therapy and induce cell death through mitochondrial damage and cell cycle arrest. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:110 / 117
页数:8
相关论文
共 45 条
[21]   Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells [J].
Karimi, M ;
Cao, TM ;
Baker, JA ;
Verneris, MR ;
Soares, L ;
Negrin, RS .
JOURNAL OF IMMUNOLOGY, 2005, 175 (12) :7819-7828
[22]   Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein [J].
Kotha, A ;
Sekharam, M ;
Cilenti, L ;
Siddiquee, K ;
Khaled, A ;
Zervos, AS ;
Carter, B ;
Turkson, J ;
Jove, R .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (03) :621-629
[23]  
Kowaltowski A. J., 2001, MITOCHONDRIA PATHOGE, P281
[24]   Mitochondrial control of cell death [J].
Kroemer, G ;
Reed, JC .
NATURE MEDICINE, 2000, 6 (05) :513-519
[25]   Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α [J].
Lagouge, Marie ;
Argmann, Carmen ;
Gerhart-Hines, Zachary ;
Meziane, Hamid ;
Lerin, Carles ;
Daussin, Frederic ;
Messadeq, Nadia ;
Milne, Jill ;
Lambert, Philip ;
Elliott, Peter ;
Geny, Bernard ;
Laakso, Markku ;
Puigserver, Pere ;
Auwerx, Johan .
CELL, 2006, 127 (06) :1109-1122
[26]  
Li WQ, 1999, CELL GROWTH DIFFER, V10, P769
[27]   Chk1-dependent regulation of Cdc25B functions to coordinate mitotic events [J].
Loeffler, Harald ;
Rebacz, Blanka ;
Ho, Anthony D. ;
Lukas, Jiri ;
Bartek, Jiri ;
Kraemer, Alwin .
CELL CYCLE, 2006, 5 (21) :2543-2547
[28]   Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein [J].
Lopez-Girona, A ;
Furnari, B ;
Mondesert, O ;
Russell, P .
NATURE, 1999, 397 (6715) :172-175
[29]   Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel [J].
Mabuchi, S ;
Ohmichi, M ;
Kimura, A ;
Hisamoto, K ;
Hayakawa, J ;
Nishio, Y ;
Adachi, K ;
Takahashi, K ;
Arimoto-Ishida, E ;
Nakatsuji, Y ;
Tasaka, K ;
Murata, Y .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (36) :33490-33500
[30]   Current management of ovarian carcinosarcoma [J].
Mano, M. S. ;
Rosa, D. D. ;
Azambuja, E. ;
Ismael, G. ;
Braga, S. ;
D'Hondt, V. ;
Piccart, M. ;
Awada, A. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (02) :316-324